Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaffer Ajani

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Diseases of the Colon and Rectum|July 9, 2014
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen studyErin M Siegel, Steven Eschrich, Kathryn Winter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation responseJennifer Sims-Mourtada, Julie G Izzo, Smith Apisarnthanarax, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2009
Outcomes with esophageal cancer radiation therapyZhen Zhang, Yuan Chen, Yanzhi Chen, et al.
Journal of Surgical Oncology|October 16, 2019
Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancerCasey J Allen, Timothy E Newhook, Timothy J Vreeland, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapyZhen Zhang, Zhongxing Liao, Jing Jin, et al.
Cancer|August 6, 2014
A validated miRNA profile predicts response to therapy in esophageal adenocarcinomaHeath D Skinner, Jeffrey H Lee, Manoop S Bhutani, et al.
American Journal of Cancer Research|April 13, 2017
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerYuping Yin, Qian Shen, Peng Zhang, et al.
Annals of Surgical Oncology|November 8, 2013
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancerArya Amini, Jaffer Ajani, Ritsuko Komaki, et al.
The Lancet. Oncology|June 17, 2023
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 17, 2011
Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial marginsJohn A Harvin, Guy Lahat, Arlene M Correa, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Diseases of the Colon and Rectum|July 9, 2014
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen studyErin M Siegel, Steven Eschrich, Kathryn Winter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006
Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation responseJennifer Sims-Mourtada, Julie G Izzo, Smith Apisarnthanarax, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2009
Outcomes with esophageal cancer radiation therapyZhen Zhang, Yuan Chen, Yanzhi Chen, et al.
Journal of Surgical Oncology|October 16, 2019
Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancerCasey J Allen, Timothy E Newhook, Timothy J Vreeland, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2005
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapyZhen Zhang, Zhongxing Liao, Jing Jin, et al.
Cancer|August 6, 2014
A validated miRNA profile predicts response to therapy in esophageal adenocarcinomaHeath D Skinner, Jeffrey H Lee, Manoop S Bhutani, et al.
American Journal of Cancer Research|April 13, 2017
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerYuping Yin, Qian Shen, Peng Zhang, et al.
Annals of Surgical Oncology|November 8, 2013
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancerArya Amini, Jaffer Ajani, Ritsuko Komaki, et al.
The Lancet. Oncology|June 17, 2023
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studyEric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 17, 2011
Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial marginsJohn A Harvin, Guy Lahat, Arlene M Correa, et al.
Pageof 11